These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 9492120)

  • 1. Treatment of NIDDM in youth.
    Owada M; Nitadori Y; Kitagawa T
    Clin Pediatr (Phila); 1998 Feb; 37(2):117-21. PubMed ID: 9492120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alpha-glucosidase inhibitor in combination with sulphonylurea compounds on lipid profile in patients with non-insulin-dependent diabetes mellitus.
    Okada S; Ishii K; Tanokuchi S; Hamada H; Ichiki K; Ota Z
    J Int Med Res; 1995; 23(6):492-6. PubMed ID: 8746618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [25 years of diabetic treatment by oral hypoglycemic agents: successes and failures].
    Tattersall RB
    Journ Annu Diabetol Hotel Dieu; 1984; ():183-91. PubMed ID: 6443219
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide).
    Loubatiéres A; Mariani MM; Ribes G; Alric R
    Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200675
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment with glibenclamide in maturity-onset diabetes mellitus.
    Persson I; Madsen SN
    Geriatrics; 1971 May; 26(5):182-95. PubMed ID: 5004113
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination therapy of glibenclamide and insulin in NIDDM patients with secondary failure to oral drugs.
    Mohan V; Snehalatha C; Ramachandran A; Viswanathan M
    J Assoc Physicians India; 1990 Aug; 38(8):537-41. PubMed ID: 2123183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical testing of a sulfonylurea preparation (glibenclamide)].
    Sigroth K; Steen B; Svanborg A
    Lakartidningen; 1969 Nov; 66(45):4647-50. PubMed ID: 4996889
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).
    Zapecka-Dubno B; Czyzyk A; Dworak A; Bak MI
    Arzneimittelforschung; 1999 Apr; 49(4):330-4. PubMed ID: 10337452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Insulin, glibenclamide plus acarbose in diabetes mellitus?].
    Hauner H
    Dtsch Med Wochenschr; 1995 Nov; 120(46):1605. PubMed ID: 7588044
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapeutic effect of glibenclamide contrasted with other oral antidiabetic agents].
    Andreev D; Pampulov L
    Vutr Boles; 1975; 14(3):110-7. PubMed ID: 818818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular biology and diabetes: where to now?].
    Haluzík M
    Vnitr Lek; 2006 Mar; 52(3):205-6. PubMed ID: 16722150
    [No Abstract]   [Full Text] [Related]  

  • 13. [Knack of treatment with oral hypoglycemic drugs in the elderly].
    Komatsu M; Hashizume K
    Nihon Rinsho; 2006 Jan; 64(1):93-8. PubMed ID: 16408454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinico-statistical studies of the use of oral hypoglycemic agents in the therapy of diabetes: critical evaluation of their effectiveness and tolerance].
    Torri A; Zanni A; Roncaia R; Di Saverio S
    Clin Ter; 1977 Jul; 82(1):45-56. PubMed ID: 409583
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical characteristics of patients with the initial diagnosis of NIDDM with positivity for antibodies to glutamic acid decarboxylase.
    Inukai T; Fujiwara Y; Tayama K; Aso Y; Ogino K; Takemura Y
    Exp Clin Endocrinol Diabetes; 1997; 105(6):327-30. PubMed ID: 9439927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The beta cell function in NIDDM patients with secondary failure: a three year follow-up of combined oral hypoglycemic and insulin therapy.
    Greco AV; Caputo S; Bertoli A; Ghirlanda G
    Horm Metab Res; 1992 Jun; 24(6):280-3. PubMed ID: 1634193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary failure of oral hypoglycaemic agents in lean patients with type 2 diabetes mellitus: insulin sensitivity, insulin response to different stimuli, and the role of cyclic-AMP.
    Pontiroli AE; Caviezel F; Alberetto M; Secchi A; Capra F; Bonisolli L; Calderara A; Pozza G
    Diabete Metab; 1992; 18(1):25-31. PubMed ID: 1314198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral management of uncomplicated maturity onset diabetes.
    Mashaly M; el-Ebrashy N; Higazi AM; Einen MA; Aziz MT
    J Egypt Med Assoc; 1974; 57(7-8):288-97. PubMed ID: 4217809
    [No Abstract]   [Full Text] [Related]  

  • 19. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S; Estacio RO; Jeffers B; Schrier RW
    Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of octreotide on glucose and insulin levels in a patient with type 2 diabetes on glibenclamide.
    Lee PE; Meneilly GS
    Diabetes Metab; 1999 Sep; 25(4):347-9. PubMed ID: 10566126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.